Resource Logo
AIDS Weekly Plus

Studies from Veterans Affairs Medical Center Update Current Data on HIV/AIDS


2012 NOV 5 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- New research on Immune System Diseases and Conditions is the subject of a report. According to news reporting originating from Richmond, Virginia, by NewsRx correspondents, research stated, "HIV protease inhibitors (PIs) are the cornerstone of Highly Active Antiretroviral Therapy (HAART). Their antiretroviral potent is attributable to their pharmacokinetic properties."

Our news editors obtained a quote from the research from Veterans Affairs Medical Center, "Yet, as the pharmacologic target of HIV PIs is localized within HIV-infected cells, cellular pharmacokinetic properties must also be determined to predict not only efficacy, but also toxicity. In this review, we review recent studies about cellular pharmacokinetics of current marketed HIV PIs, as well as the physicochemical properties of HIV PIs and their drug transporters and enzymes. Additionally, a summary of potential strategies for optimizing cellular pharmacokinetics of HIV PIs and initial ideas to study cellular pharmacokinetics is also discussed."

According to the news editors, the research concluded: "Cellular pharmacokinetics of HIV PIs is an important budding field of research that will significantly influence efficacy and toxicity profiles of these essential drugs, and we hope our review will aid in fundamental knowledge for future research."

For more information on this research see: The Cellular Pharmacokinetics of HIV Protease Inhibitors: Current Knowledge and Future Perspectives. Current Drug Metabolism, 2012;13(8):1174-1183. Current Drug Metabolism can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers -; Current Drug Metabolism -

The news editors report that additional information may be obtained by contacting W.B. Zha, McGuire Dept. of Vet Affairs Med Center, Richmond, VA, United States (see also Immune System Diseases and Conditions).

Keywords for this news article include: Antiretrovirals, Pharmaceuticals, Drugs, Therapy, Richmond, Virginia, HIV/AIDS, RNA Viruses, HIV Protease, United States, HIV Infections, Viral Proteins, Pharmacokinetics, Enzyme Inhibitors, Peptide Hydrolases, Vertebrate Viruses, Protease Inhibitors, Primate Lentiviruses, Enzymes and Coenzymes, Retroviridae Proteins

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC


Copyright © 2012 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.

Information in this article was accurate in November 5, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.